MedTrace Logo

Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)

NCT01947738 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2013-12-31

No results posted yet for this study

Summary

Psoriasis is an inflammatory autoimmune disease that might be controlled by a cathepsin S inhibitor like VBY-891.

Conditions

  • Healthy

Interventions

DRUG

VBY-891

Cathepsin S inhibitor

DRUG

Placebo

Sponsors & Collaborators

  • LEO Pharma

    collaborator INDUSTRY

  • Virobay Inc.

    lead INDUSTRY

Principal Investigators

  • David B. Karpf, MD · Virobay Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01947738 on ClinicalTrials.gov